Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1915 1
1917 1
1926 1
1940 2
1942 1
1943 1
1944 1
1946 5
1947 5
1948 9
1949 4
1950 4
1951 4
1952 4
1953 1
1954 1
1955 2
1956 2
1957 2
1958 2
1959 3
1961 3
1965 2
1966 2
1967 1
1969 1
1971 1
1972 2
1973 2
1974 1
1975 5
1976 4
1977 3
1978 1
1979 2
1980 3
1982 4
1983 9
1984 2
1985 2
1986 8
1987 7
1988 7
1989 8
1990 12
1991 9
1992 16
1993 10
1994 17
1995 21
1996 14
1997 19
1998 30
1999 11
2000 15
2001 14
2002 12
2003 12
2004 14
2005 19
2006 15
2007 16
2008 16
2009 13
2010 8
2011 9
2012 18
2013 16
2014 19
2015 14
2016 18
2017 18
2018 22
2019 20
2020 23
2021 30
2022 36
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

681 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: swanson cj. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. Swanson CJ, et al. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Alzheimers Res Ther. 2021. PMID: 33865446 Free PMC article. Clinical Trial.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: swanson cj. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
The importance of the circadian system & sleep for bone health.
Swanson CM, Kohrt WM, Buxton OM, Everson CA, Wright KP Jr, Orwoll ES, Shea SA. Swanson CM, et al. Metabolism. 2018 Jul;84:28-43. doi: 10.1016/j.metabol.2017.12.002. Epub 2017 Dec 9. Metabolism. 2018. PMID: 29229227 Free PMC article. Review.
Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology-Pathology Working Group.
Smedley RC, Bongiovanni L, Bacmeister C, Clifford CA, Christensen N, Dreyfus JM, Gary JM, Pavuk A, Rowland PH, Swanson C, Tripp C, Woods JP, Bergman PJ. Smedley RC, et al. Among authors: swanson c. Vet Comp Oncol. 2022 Dec;20(4):739-751. doi: 10.1111/vco.12827. Epub 2022 Jul 4. Vet Comp Oncol. 2022. PMID: 35522017 Free PMC article. Review.
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, Johnson KA, Aisen PS. Rafii MS, et al. Among authors: swanson cj. Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15. Alzheimers Dement. 2023. PMID: 35971310 Free PMC article.
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.
Hayato S, Takenaka O, Sreerama Reddy SH, Landry I, Reyderman L, Koyama A, Swanson C, Yasuda S, Hussein Z. Hayato S, et al. Among authors: swanson c. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36165093 Free PMC article.
681 results